Safety and efficacy of hepatic arterial infusion chemotherapy combined with anti-PD-1 monoclonal antibody in the treatment of hepatocellular carcinoma with microvascular invasion
10.3969/j.issn.1008-794X.2025.06.012
- VernacularTitle:肝动脉灌注化疗联合抗PD-1单克隆抗体治疗肝细胞癌伴微血管侵犯患者安全性和有效性
- Author:
Fengtao ZHANG
1
Author Information
1. 510000 广东深圳 华中科技大学协和深圳医院介入科
- Keywords:
hepatic arterial infusion chemotherapy;
programmed death-1 monoclonal antibody;
vascular invasion;
advanced hepatocellular carcinoma;
propensity score matching
- From:
Journal of Interventional Radiology
2025;34(6):624-630
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the safety and efficacy of hepatic arterial infusion chemotherapy(HAIC)combined with anti-PD-1 monoclonal antibody(anti-PD-1 mAb)in treating advanced hepatocellular carcinoma(HCC)with microvascular invasion(MVI).Methods The clinical data of 156 patients with advanced HCC,who received HAIC-mFOLFOX6 combined with anti-PD-1 mAb(HAIC-PD-1 group,n=61)or received simple HAIC-mFOLFOX6(simple HAIC group,n=95)at the Union Shenzhen Hospital,Huazhong University of Science and Technology of China From January 2018 to December 2021,were retrospectively collected.After propensity score matching(PSM)for 156 patients,the overall cohort and the matched cohort(PSM cohort)were obtained.The differences in overall survival(OS)and progression-free survival(PFS)were compared between the two cohorts.Based on the modified Response Evaluation Criteria in Solid Tumors(mRECIST)the tumor response to treatment was evaluated.The objective response rate(ORR)and disease control rate(DCR)were compared between the overall cohort and the PSM cohort.Univariate analysis and multivariate analysis were used to identify the independent predictive factors affecting OS and PFS.Results In both the overall cohort and the PSM cohort,the OS and PFS in the HAIC-PD-1 group were better than those in the simple HAIC group(both P＜0.01),while no statistically significant differences in ORR and DCR existed between the HAIC-PD-1 group and the simple HAIC group(both P＞0.05).Multivariate analysis showed that ALBI grade and therapeutic method were the independent predictive factors for OS,while extrahepatic metastases and therapeutic method were the independent predictive factors for PFS.Conclusion In treating patients with advanced HCC complicated by MVI,H AIC-mFOLFOX6 combined with anti-PD-1 mAb carries more significant survival benefits when compared with simple HAIC-mFOLFOX6.In aspect of controlling the tumor progression,HAIC-mFOLFOX6 combined with anti-PD-1 mAb and simple HAIC-mFOLFOX6 have similar efficacy.
